Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC ...Middle East

HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC )

Also on site :

• Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
• Iran threatens US bases in Middle East, asserts nuclear facilities undamaged
• Las negociaciones “no tienen sentido” a menos que Israel detenga los ataques, dice un portavoz del Gobierno iraní a CNN